Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099132 | 1.00 | RAB9A (0.53) | RAB9AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5104004 | 0.87 | RAB9A (0.49) | RAB9AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2055260 | 0.87 | MAPT (0.50) | RAB9AALDH1A1MAPTMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL2099569 | 0.86 | RAB9A (0.46) | RAB9AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2099417 | 0.85 | ALDH1A1 (0.56) | RAB9AALDH1A1MAPTNPC1APOBEC3A | |
| SCHEMBL5140574 | 0.84 | RAB9A (0.44) | RAB9AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5140575 | 0.84 | RAB9A (0.44) | RAB9AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31589586 | 0.80 | MGLL (0.60) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1725148 | 0.77 | MAPT (0.68) | ALDH1A1MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1725143 | 0.77 | MAPT (0.68) | ALDH1A1MAPTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957215-B2 | Heteroaryl substituted benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | ASTRAZENECA AB (SE) | 2012-08-16 | — | — | US | disclosed |
| US-8163928-B2 | Heteroaryl substituted benzothiazoles | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1981883-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007086800-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | APP, MAPT, PSEN1 | RAB9A 2522/4885ALDH1A1 2100/4885MAPT 2/4885 |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | MAPT, APP, PSEN1 | RAB9A 3260/4885ALDH1A1 1704/4885MAPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.